top of page

AOA Dx News Exclusive: Liquid-biopsy startup closes $17M to fund ovarian cancer diagnostic test

Oriana Papin-Zoghbi, AOA Dx CEO
Oriana Papin-Zoghbi, AOA Dx CEO

We are proud to announce we have just closed an oversubscribed $17 million investment round, bringing our total funding to date to $24 Million. This round was led by Good Growth Capital with participation from industry leading investors including RH Capital, Y Combinator, Astia, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, FemHealth Ventures, CANCER FUND along with strategic diagnostic investors, including Labcorp Venture Fund!

We are immensely grateful for the support and belief from our partners.

At AOA Dx, our journey began with a vision to bridge the gap in healthcare disparities for women. Ovarian cancer has taken too many lives, and we're here to change that through the power of novel biomarkers: tumor marker gangliosides. For decades women have been neglected in research, data and innovation. This funding will bring us one step closer to developing the first early detection test for ovarian cancer, and further develop our GlycoLocate™ platform into various new cancer areas.

We extend our heartfelt gratitude to our team - your dedication & commitment have brought us to this point.

As we continue to grow AOA, we will be hiring talented scientists who share a passion for creating a better future for cancer patients! Please reach out to us to learn more.

Thank you Anna Brown at Endpoints News for sharing our story!


bottom of page